Tricida to Provide an End-of-Year Business Update
Tricida, Inc. (Nasdaq: TCDA) announced it will provide a business update on its investigational drug veverimer (TRC101), aimed at treating metabolic acidosis in chronic kidney disease (CKD) patients.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Tricida, Inc. (Nasdaq: TCDA) announced it will provide a business update on its investigational drug veverimer (TRC101), aimed at treating metabolic acidosis in chronic kidney disease (CKD) patients. The update will cover development, regulatory status, and patent protection. A conference call is scheduled for December 8, 2020, at 4:30 PM ET, which will be accessible via webcast and dial-in. Veverimer is designed to address metabolic acidosis, a common complication in CKD affecting approximately three million patients in the U.S.
Positive
- Tricida will provide an update on veverimer's development and regulatory status, indicating ongoing progress.
- The drug targets metabolic acidosis in CKD, which affects a significant patient population, suggesting potentially meaningful market demand.
Negative
- None.
Details
News Market Reaction – TCDA
The recorded move for TCDA in the trading session of this news was +8.85%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SOUTH SAN FRANCISCO, Calif., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Tricida, Inc. (Nasdaq: TCDA), a pharmaceutical company focused on the development and commercialization of its investigational drug candidate, veverimer (TRC101), a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with chronic kidney disease (CKD), announced today that it will provide an end-of-year business update on veverimer’s development program, regulatory status and patent protection.
Tricida will host a conference call and webcast at 4:30 pm Eastern Time on December 8, 2020. The webcast, including slides, or conference call may be accessed as follows:
| Tricida Update End-of-Year Business Update Conference Call | |
| Tuesday, December 8, 2020 4:30 pm Eastern Time | |
| Webcast: | IR.Tricida.com |
| Dial-in: | (877) 377-5478 |
| International: | (629) 228-0740 |
| Conference ID: | 2669339 |
A replay of the webcast will be available on Tricida’s website approximately two hours following the completion of the call and will be available for up to 90 days following the presentation.
About Tricida
Tricida, Inc. is a pharmaceutical company focused on the development and commercialization of its drug candidate, veverimer (TRC101), a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with CKD. Metabolic acidosis is a condition commonly caused by CKD that is believed to accelerate the progression of kidney deterioration. It is estimated to pose a health risk to approximately three million patients with CKD in the United States.
For more information about Tricida, please visit www.tricida.com.
Contact:
Jackie Cossmon, IRC
Tricida, Inc.
Senior Vice President of
Investor Relations and Communications
IR@Tricida.com
Source: Tricida, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.